Barely Significant
← all phrases

borderline significant

2,001 sentences · 2,001 papers · 13,524 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

borderline significantp = 0.051.0× alphagold
During almost 20 years of follow-up across all IJD categories, OI occurred more often in RA (17.9%) than PsA (12.6%) or AS patients (13.3%) ( p = 0.002) with a significantly higher overall OI incidence rate in RA patients than in PsA and AS patients (both p < 0.01) while the rate difference between PsA and AS was borderline significant ( p = 0.05) (Table 2 ).
borderline significantP =0.051.0× alphagold
Shown in Figure 2 , meta‐analysis of dichotomous cerebrovascular reactivity revealed a borderline significant association between an impaired cerebrovascular reactivity and an increased prevalence of cSVD (dichotomous predictor pooled OR, 2.26 [95% CI, 0.99–5.14], P =0.05).
borderline significantp = 0.051.0× alphagold
no significant difference between first responders that participated in special operations or non-special operations regarding the importance of health monitoring preferences; (6) there was a significant association between age group of the respondent and cortisol levels (stress) ( p = 0.02) and a borderline significant association between age group of the respondent and skin resistance ( p = 0.05); (7) there was a significant association between special operations and biological proteins ( p = 0.03); and (8) there was a significant association between age group of the respondent and carbon dioxide ( p = 0.03).
borderline significantp = 0.051.0× alphagold
Similar observations were demonstrated in the CON group, with a borderline significant ( p = 0.05) reduction in SBP of −1.4 mmHg [−2.8;0.0] and a significant ( p = 0.03) reduction in DBP of −1.5 mmHg [−2.8;−0.1], resulting in a reduction ( p = 0.01) in MAP of −1.5 mmHg [−2.6;−0.3].
borderline significantp = 0.051.0× alphagold
rvention with vorapaxar as compared with placebo. PAI-2 decreased significantly in favor of vorapaxar as compared with placebo in the total study population ( p = 0.025) at late FU, essentially driven by changes in the post-MI (chronic CHD) patients ( p = 0.054), whereas vorapaxar induced a borderline significant increase ( p = 0.05) in NSTEMI (TRACER) patients during short-term therapy ( Table 6 ).